Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Think Research Corporation THKKF


Primary Symbol: V.THNK

Think Research Corporation is a Canada-based company that offers digital health software solutions. It is a provider of cloud-based data, knowledge, and software solutions primarily delivered as software-as-a-service (SaaS) to healthcare delivery systems and the practitioners that they support. Its operations are organized into three lines of business: Software and Data Solutions, Clinical Research, and Clinical Services. Its SaaS solutions help patients find, navigate, and connect to health services across large governments and payer clients, while also ensuring safety for prescribed medications at pharmacies. Through its wholly owned subsidiary, BioPharma Services Inc., the Company provides research data and analysis derived from Phase I clinical trials, bioequivalence studies and bioanalytical services. Its clinics act as a test bed for its software and technology, transforming them with digital solutions that optimize clinical outcomes, streamline workflows, and optimize billing.


TSXV:THNK - Post by User

Comment by dt_coreon Apr 12, 2022 10:48am
121 Views
Post# 34596792

RE:Think Webcast Live at VirtualInvestorConferences Apr 7 10am

RE:Think Webcast Live at VirtualInvestorConferences Apr 7 10amFor the most part the pitch has remained constant however SA cited analyst 2022 estimates rather than prior Think Research guidance in terms of outlook. Analysts estimate $91mm in rev vs. guidance of $90mm to $100mm in rev for 2022. No explanation was given as to why the change so investors are left to interpret. Combine that with the CFO departure and the optics look terrible. Explanations for the share price being so low during the presentation were repeated (i.e. lock-up period ending, tax loss selling, being a small cap company).

Reality however is that most analysts reduced their estimates due to expected Q1 pressures related to temporary COVID lockdown measures and a resumption of growth thereafter in line with management. That is quite logical but without explanation by SA it looks like the company is failing to deliver rather than it being a temporary issue PLUS not providing any explanation for the shift makes it look like Think is trying to hide something or embarrased to acknowledge (even if reality is quite different). Regarding the CFO departure, Jae has a long history of very short stays at employers before jumping to a new opportunity. SA probably should have considered that before hiriing him. The CFO has also recently been selling shares, possibly automated and related to his departure.

Oak Hill in their agreement with Think Research has likely already been issued cheap shares (it was to be anytime after April 1st). Ideally this means that the incentive now exists for them to boost the price vs. prior their incentive was to see the share price get as low as possible to maximize the number of shares they would recieve.
<< Previous
Bullboard Posts
Next >>